J. Schoenfeld, Y.H. Chen, L. Gunasti, A. Droznin, J. Baginska, A. Nau, J. Weirather, I. G. Diaz, D.N. Margalit, R. Tishler, K. J. Fitzgerald, R.H. Mak, R. Uppaluri, K. Sehgal, G.J. Hanna, R. Haddad, J. So
{"title":"抗-PD-1疗法治疗复发或转移性头颈部鳞状细胞癌患者进展后,Pembrolizumab联合放疗的2期临床试验","authors":"J. Schoenfeld, Y.H. Chen, L. Gunasti, A. Droznin, J. Baginska, A. Nau, J. Weirather, I. G. Diaz, D.N. Margalit, R. Tishler, K. J. Fitzgerald, R.H. Mak, R. Uppaluri, K. Sehgal, G.J. Hanna, R. Haddad, J. So","doi":"10.1016/j.ijrobp.2024.01.075","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"12 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck\",\"authors\":\"J. Schoenfeld, Y.H. Chen, L. Gunasti, A. Droznin, J. Baginska, A. Nau, J. Weirather, I. G. Diaz, D.N. Margalit, R. Tishler, K. J. Fitzgerald, R.H. Mak, R. Uppaluri, K. Sehgal, G.J. Hanna, R. Haddad, J. So\",\"doi\":\"10.1016/j.ijrobp.2024.01.075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14219,\"journal\":{\"name\":\"International Journal of Radiation Oncology*Biology*Physics\",\"volume\":\"12 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology*Biology*Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.01.075\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Phase 2 Clinical Trial of Pembrolizumab with Radiation Following Progression on anti-PD-1 Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck